NEW YORK, Sept. 2, 2015 /PRNewswire/ -- The report on breast cancer therapeutics: pipeline analysis market studies the future market of breast cancer drugs on the basis of the molecules which are currently under pipeline. Breast cancer usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. This is a malignant type of tumor that can spread to other cells present in the body. The type of cancer which starts in lobules is referred as lobular carcinoma, while the other that develops from milk ducts is called ductal carcinoma. Breast cancer is the most common type of invasive cancer affecting women worldwide. The drugs that are under clinical trial phase III have been considered to estimate the market for the forecast period from 2015 to 2023. Stakeholders for this report include the companies engaged in research and development of breast cancer drugs, and sponsoring of clinical trials studies and new entrants that are planning to invest in the breast cancer pipeline drugs.
The executive summary section of the breast cancer therapeutics: pipeline analysis market report summarizes the market analysis of the major pipeline drugs in the breast cancer market. It also provides information about the key pipeline molecules available in phase I and phase II clinical trials along with a list of major market players who are sponsoring these studies.
The market overview section of the report provides a detailed qualitative information about breast cancer. Factors such as epidemiology of breast cancer across different geographical regions, types of breast cancer, and other possible treatments for breast cancer are explained along with relevant statistics in this section. A list of companion diagnostic devices with respect to the major target drugs used for the treatment of breast cancer is also included in the report to provide a brief idea about the current scenario of the breast cancer market. Major business strategies applied in the market by the major players to strengthen their breast cancer pipeline have also been explained with the help of relevant examples. All these factors have been provided to help new entrants and market players understand the important aspects of the breast cancer market in the current scenario and decide upon strategic decisions that would assist them in generating a strong pipeline for breast cancer therapeutic drugs.
Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) + Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine + Pertuzumab. Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023.
A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi.
Read the full report: http://www.reportlinker.com/p03207045-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
